Iron deficiency anemia is the most prevalent nutritional anemia in children across the globe, and pediatricians encounter it daily. The standard diagnostic playbook is well rehearsed: assess dietary iron intake, screen for hereditary conditions such as thalassemia or sickle cell disease, look for overt or occult blood loss, and consider impaired absorption. In this patient, the workup initially revealed a classic microcytic, hypochromic pattern on his complete blood count — red cells that were both smaller and paler than normal, with a reduced mean corpuscular hemoglobin — alongside biochemical markers confirming genuine iron depletion. His diet was adequate, and there was no family history to suggest an inherited anemia. That left the uncomfortable question of where his iron was going.

The answer, it turned out, was seeping away invisibly. Upper gastrointestinal endoscopy revealed ulcers in both the stomach and the duodenum, accompanied by H. pylori-associated gastritis. Chronic oozing from these lesions, too slow to ever produce visible blood in the stool, had been draining the boy’s iron reserves for months. The bacteria itself was confirmed with a carbon-13 urea breath test, a noninvasive diagnostic in which the patient ingests urea labeled with a stable isotope; H. pylori’s urease enzyme splits the urea, releasing labeled carbon dioxide that can be measured in exhaled breath. A positive result, combined with the endoscopic picture, gave the team a coherent etiological story: infection, ulceration, occult bleeding, and iron loss.

What makes the case striking is the complete absence of gastrointestinal symptoms. Peptic ulcer disease in adults typically announces itself with epigastric pain, often related to meals, and children are generally assumed to present similarly. This patient felt nothing in his abdomen. The authors of the report emphasize that this silence delayed consideration of gastrointestinal pathology altogether, a delay they argue is not merely anecdotal but representative of a broader blind spot in clinical practice, particularly in regions where H. pylori prevalence is high.

The biology behind this presentation is well characterized even when the clinical presentation is not. H. pylori colonizes the gastric mucosa, where it disrupts the protective mucus layer, triggers chronic inflammation, and can cause erosions and ulcers. At the same time, the organism competes directly with its host for iron: it expresses receptors that bind human lactoferrin and other iron-containing proteins, effectively pirating the micronutrient for its own metabolism. Chronic gastritis can also reduce gastric acid output and ascorbic acid levels, both of which are needed to convert dietary ferric iron into the ferrous form that the duodenum absorbs. The result is a double hit — ongoing blood loss plus impaired iron uptake — that can outpace any dietary compensation.

In children, the stakes of missing this diagnosis compound over time. Iron is essential not only for hemoglobin synthesis but for neurocognitive development, immune function, and physical growth. Prolonged deficiency during school-age years has been associated with fatigue, reduced exercise tolerance, and difficulties with concentration. An ulcer that goes untreated, meanwhile, carries risks of its own, including more significant hemorrhage, perforation, and scarring. Early identification of H. pylori as the driver therefore converts a potentially progressive, insidious illness into a readily reversible one: eradication therapy combining antibiotics with a proton pump inhibitor, followed by confirmation of cure, typically resolves both the infection and its hematological consequences.

The report’s authors, a team of pediatricians and gastroenterologists affiliated with hospitals in Jiashan, Shanghai, and Hangzhou, argue that refractory or unexplained iron deficiency anemia in children should prompt clinicians to look beyond the usual suspects. Even in the absence of abdominal pain, they recommend that H. pylori infection and peptic ulcer disease enter the differential diagnosis once dietary inadequacy, hereditary anemias, and other common causes of iron loss have been excluded. Noninvasive testing such as the urea breath test makes this a practical proposition even in primary care settings, though definitive characterization of mucosal disease still requires endoscopy.

The epidemiological backdrop gives the recommendation added urgency. H. pylori infects roughly half of the world’s population, with prevalence substantially higher in developing regions and in communities with crowded living conditions and limited sanitation. Most infected individuals never develop symptomatic disease, which is precisely what makes the infection so easy to overlook when it does cause harm. In pediatrics, where complaints are often vague and children may not articulate discomfort clearly, an asymptomatic presentation is less an anomaly than a hazard baked into the disease’s natural history.

There is also a lesson here about the limits of symptom-driven medicine. The traditional diagnostic heuristic — follow the patient’s complaints — works well for acute conditions but can fail for slow-burning processes that announce themselves only through laboratory abnormalities. A hemogram showing microcytic anemia is not a diagnosis; it is a question. In this case, answering that question required the clinical team to resist the reassuring absence of symptoms and pursue invasive and noninvasive testing until the source of iron loss was found. The boy’s pallor and fatigue were, in effect, the surface expression of a subterranean hemorrhage.

For clinicians, the takeaway is concrete: in a child with iron deficiency anemia that does not respond as expected to iron supplementation, or in which no dietary or hereditary explanation exists, testing for H. pylori deserves a place early in the workup rather than as a last resort. For parents, the message is subtler but no less important — persistent pallor and fatigue in a child warrant medical evaluation even when the child insists he feels fine. A bacterium as widespread and as quiet as H. pylori does not always announce its presence; sometimes the only evidence it leaves behind is in the blood count.

Subject of Research: Helicobacter pylori-related peptic ulcer disease presenting as isolated iron deficiency anemia in a child

Article Title: Helicobacter pylori-related peptic ulcer presenting as isolated iron deficiency anemia without typical gastrointestinal complaints in a child: a case report

Article References: Chen, X., Miao, S., Zou, S., Wang, Y., Chen, G., & Jiang, M. (2026). Helicobacter pylori-related peptic ulcer presenting as isolated iron deficiency anemia without typical gastrointestinal complaints in a child: a case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14366-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14366-4

Keywords: Helicobacter pylori, iron deficiency anemia, peptic ulcer, pediatrics, endoscopy, urea breath test, gastrointestinal bleeding, anemia, gastritis, case report, occult blood loss, BMC Infectious Diseases

The central obstacle is gastrointestinal toxicity. During the first infusion of zolbetuximab, many patients experience waves of nausea and vomiting that can be severe enough to frighten them away from subsequent cycles. In the pivotal phase III trials SPOTLIGHT and GLOW, which tested the antibody alongside mFOLFOX6 and CAPOX chemotherapy respectively, these early gastrointestinal events were the most frequent reason for dose delays and interruptions. Sagawa and colleagues contend that these symptoms are not random collateral damage but an expected consequence of the drug’s mechanism, arising when the antibody binds claudin 18.2 on healthy gastric mucosal cells as well as on tumor cells. That binding can trigger a distinctive, often transient gastritis, and the resulting inflammation of the stomach lining appears to feed directly into nausea, loss of appetite, and declining serum albumin levels. In their framing, nausea, vomiting, gastritis, anorexia, and hypoalbuminemia should be understood as interconnected on-target toxicities sharing a common origin in the stomach.

Some of the most intriguing evidence for this idea comes from endoscopy. In a study characterizing early-onset gastritis during zolbetuximab-containing chemotherapy, fully 89.7 percent of evaluated patients showed gastric inflammation on endoscopic examination within the early treatment period. Crucially, patients whose gastritis was diffuse rather than localized reported anorexia more frequently and experienced steeper declines in serum albumin. This pattern suggests a plausible physiological chain: the antibody injures the mucosa, the injured stomach generates nausea and suppresses appetite, reduced nutritional intake drives protein levels down, and the cumulative burden threatens both the patient’s condition and their willingness to continue therapy. Animal work offers supporting context, with ferret studies showing that gastric injury accompanies zolbetuximab-induced emesis and that certain antiemetics can mitigate both.

The Japanese experience adds a compelling and somewhat puzzling layer to the story. In a combined subgroup analysis of Japanese patients enrolled in SPOTLIGHT and GLOW, the progression-free survival benefit was markedly larger than in the overall trial populations, with a median of 20.53 months and a hazard ratio of 0.482, compared with hazard ratios of roughly 0.69 to 0.75 in the full cohorts. Japanese patients also tolerated the drug remarkably well: relative dose intensity exceeded 80 percent in 98.2 percent of Japanese participants versus 88.9 percent of non-Japanese patients, and not a single Japanese patient discontinued zolbetuximab permanently because of nausea or vomiting. The authors are careful to describe these findings as hypothesis-generating rather than proof. Higher cumulative drug exposure achieved through meticulous supportive care may partly explain the superior outcomes, but biological differences, population characteristics, and the intensive follow-up culture of Japanese oncology centers could all contribute, and disentangling these factors will require prospective study.

That said, a formal pharmacokinetic analysis gives the dose-delivery hypothesis real teeth. Researchers examining the clinical pharmacology of zolbetuximab found that patients with higher average concentrations of the antibody throughout treatment, a metric abbreviated Cave, lived longer without progression and longer overall. The antibody’s pharmacokinetics follow a predictable pattern in which tumor burden influences drug clearance, which complicates simple interpretation, but the association between sustained exposure and survival provides a mechanistic bridge between the supportive-care question and the efficacy question. If side effects force dose reductions and delays, drug levels fall, and the survival advantage may erode with them. The authors stress, however, that pharmacokinetic associations do not by themselves establish causality, and that only prospective trials testing supportive-care interventions against efficacy endpoints can settle the matter.

What makes the review practically valuable is its synthesis of the management strategies that have accumulated since the drug entered routine use. A RAND/UCLA modified Delphi panel brought together international experts to forge consensus guidance on preventing and treating zolbetuximab-related nausea and vomiting, and the recommendations converge on treating the first infusion as a high-emetic-risk event. That means aggressive prophylaxis with antiemetic regimens of the kind reserved for the most emetogenic chemotherapy, delivered before the antibody ever enters the vein. Beyond drugs, pragmatic institutional protocols have emerged describing stepwise escalation of the infusion rate, beginning slowly and accelerating as the first hours pass without symptoms, on the logic that the emetic reaction is concentrated at the start of exposure.

Real-world programs have validated this playbook. The Project VYLOY initiative in Japan assembled a practical framework for administration, and a retrospective supportive-care cohort study of a standardized administration protocol reported that a combination of high-risk antiemetic prophylaxis, gradual infusion-rate escalation, temporary interruption when symptoms appear, rescue antiemetics, intravenous hydration, and structured education of both patients and clinic staff can meaningfully improve tolerability and reduce interruptions in later cycles. The emphasis on education reflects a hard-won lesson from early clinical experience: patients who understand that first-infusion symptoms typically improve in subsequent cycles, and staff who know to slow or pause the infusion rather than abandon it, are far more likely to complete the intended course of therapy. Pharmacists, in this model, are not dispensers but protocol architects who tailor antiemetic combinations and manage drug interactions with the accompanying chemotherapy.

The multidisciplinary framing is where the review makes its most distinctive argument. Managing zolbetuximab toxicity, the authors contend, cannot be the oncologist’s job alone. Physicians must anticipate and grade the toxicities, nurses must recognize the earliest signs of infusion reactions and coach patients through the vulnerable first cycle, and pharmacists must design and adjust prophylaxis. Dietitians and nutrition support enter the picture when anorexia and hypoalbuminemia threaten nutritional status, because albumin decline is both a marker of deteriorating tolerance and potentially a driver of worse outcomes in its own right. The review’s integrated model treats the stomach as the shared battleground: the same target that makes the drug effective creates the toxicity, and the toxicity, if unmanaged, undermines the effectiveness. Breaking that loop requires the whole team, not a single specialist reacting to symptoms after they appear.

For patients and families, the practical message is one of cautious reassurance. The gastrointestinal side effects of zolbetuximab are real, frequently unpleasant, and concentrated at the start of treatment, but they are manageable with proactive planning, and the evidence suggests that patients who stay on therapy reap substantial benefits. The Japanese subgroup data, whatever their ultimate explanation, demonstrate that near-complete dose delivery is achievable without anyone abandoning the drug over nausea or vomiting. For oncology practices preparing to adopt zolbetuximab, the review functions as an implementation manual: premedicate aggressively, infuse slowly at first, hydrate, monitor albumin and nutritional intake, teach patients what to expect, and resist the temptation to stop a drug whose side effects usually soften with time.

What remains open is the scientific question lurking beneath the clinical one. If supportive care truly preserves drug exposure, and drug exposure truly drives survival, then the humble antiemetic infusion protocol becomes an efficacy intervention in disguise, and clinical trials should test it as such. Until those prospective studies are done, the authors’ distinction between established evidence and generated hypotheses stands: the toxicities are established, the management strategies are supported by growing real-world data, and the claim that better supportive care directly improves survival remains a well-grounded but unproven bet. It is a striking inversion of the usual narrative of cancer drug development, where breakthroughs are celebrated for their molecular cleverness. Zolbetuximab’s ultimate legacy may depend less on the elegance of its target than on whether the medical team in the infusion chair can keep a queasy patient coming back for the next dose.

Subject of Research: Multidisciplinary management of gastrointestinal and nutritional toxicities of zolbetuximab in first-line CLDN18.2-positive gastric cancer

Article Title: Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma

Article References: Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma. (n.d.). https://doi.org/10.1007/s12032-026-03422-3

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03422-3

Keywords: zolbetuximab, claudin 18.2, gastric cancer, nausea, vomiting, gastritis, hypoalbuminemia, antiemetic prophylaxis, dose intensity, multidisciplinary care, SPOTLIGHT trial, GLOW trial